United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) (unii: c4hqf74xmw) (rabies virus strain pm-1503-3m antigen (propiolactone inactivated) - unii:c4hqf74xmw) - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - imovax rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies. imovax rabies vaccine is approved for use in all age groups. physicians must evaluate each possible rabies exposure. local or state public health officials should be consulted if questions arise about the need for prophylaxis. (11) the following factors should be considered before antirabies prophylaxis is initiated. rabid bats have been documented in the 49 continental states, and bats are increasingly implicated as important wildlife reservoirs for variants of rabies virus transmitted to humans. transmission of rabies virus can occur from minor, seemingly underappreciated or unrecognized bites from bats (see table 2). (11) raccoons, skunks, and foxes are the terrestrial carnivores most often infected with rabies in the united states. suggestive clinical signs of rabies among wildlife cannot be interpreted reliably. all bites by such wildlife should be considered possible exposures to rabies virus. post-exposu

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] - suspension for injection - 2.5 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] excipient: albumin neomycin sulfate water for injection - post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - rabies vaccine - suspension for injection - 2.5 iu/ml - rabies vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - rabies virus (flury lep) inactivated - infus/pdr/oral soln - >= 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - inactivated rabies virus strain pm/wi 38 1503 3m - powder and solvent for suspension for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - rabies virus (inactivated) - rabies virus (inactivated) 0 vaccine - vaccine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur - rabies virus inactivated - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - rabies immunoglobulin human - solution for injection - 500unit

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - rabies, inactivated, whole virus - powder and solvent for solution for injection - rabies, inactivated, whole virus 2.5 iu/ml - rabies, inactivated, whole virus - rabies, inactivated, whole virus - rabipur is indicated for active immunization against rabies in individuals of all ages.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies immune globulin (human) heat treated, imogam rabies – ht, in conjunction with the standard series of rabies vaccine vaccinations, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with rabies vaccine. previously immunized persons are those who have had a documented rabies virus neutralizing antibody titer and who have completed one of the recommended regimens (pre-exposure or post-exposure) with a cell culture vaccine or another vaccine. administer only vaccine to these persons (i.e., post-exposure for a person previously vaccinated). (1) inject imogam rabies – ht, as promptly as possible after exposure, along with the first dose of vaccine. if initiation of treatment is delayed for any reason, still administer imogam rabies – ht and the first dose of vaccine, regardless of the interval between exposure and treatment. if rabies immune globulin (human) was not administered when vaccination was begun